Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation

AstraZeneca

Status: Completed

Conditions: Bronchial Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT01232322

D5257L00014

Details and patient eligibility

About

The purpose of this study is to investigate the safety and efficacy for long term treatment of the drug in children aged 6 months and < 5 years on bronchial asthma in daily clinical usage.

Enrollment: 633 patients

Sex: All

Ages: 6 months to 5 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients treated with Pulmicort Respules for the first time due to bronchial asthma
• Children of >= 6 months and < 5 years old age at the start of study treatment

Trial design

633 participants in 1 patient group

Pulmicort Respules

Description:

Those with an exposure